Artiva Biotherapeutics (ARTV) Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Current Assets data on file, last reported at $88.7 million in Q1 2026.

• Current Assets for Q1 2026 came in at $88.7 million, down 47.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.7 million (down 47.8% YoY), and the FY2025 annual result was $112.7 million, down 40.27% from the prior year.
• Current Assets slipped to $88.7 million in Q1 2026 per ARTV's latest filing, from $112.7 million in the prior quarter.
• Over five years, Current Assets peaked at $188.6 million in Q4 2024 and troughed at $49.7 million in Q2 2024.
• A 4-year average of $124.3 million and a median of $129.5 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2025 and 2026: Current Assets jumped 199.64% in 2025, then tumbled 47.8% in 2026.
• A 4-year view of Current Assets shows it stood at $79.8 million in 2023, then surged by 136.32% to $188.6 million in 2024, then tumbled by 40.27% to $112.7 million in 2025, then dropped by 21.24% to $88.7 million in 2026.
• Business Quant data shows ARTV's Current Assets at $88.7 million in Q1 2026, $112.7 million in Q4 2025, and $129.5 million in Q3 2025.